retatrutide triple agonist gip glp-1 glucagon phase 3 2025 First-in-Class 'Triple-G'! Retatrutide, a first-in-class GIP, & hormone receptor drug leads to nearly 29% weight loss in first pivotal test! Eli Lilly announced positive topline results from the retatrutide triple agonist glp-1 gip
Description
Curious about microdosing GLP-1s
or oral administration
Gastrointestinal side effects are a little more common in the oral version than in the injectables
GLP-1 agonists are powerful weight loss tools, but certain medications can reduce their effectiveness or cause harmful interactions
These benefits span multiple biological systems including the nervous, musculoskeletal and respiratory systems
But patients are at the heart of the GLP-1 trend, and the []
